Progyny Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Progyny yıllık ortalama 14.9% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 2.1% annual. Gelirler growing yılda ortalama 29.6% oranında artmaktadır. Progyny'in özkaynak karlılığı 11.2% ve net marjı 4.3%'dir.

Anahtar bilgiler

14.94%

Kazanç büyüme oranı

14.43%

EPS büyüme oranı

Healthcare Sektör Büyümesi	8.50%
Gelir büyüme oranı	29.57%
Özkaynak getirisi	11.24%
Net Marj	4.33%
Son Kazanç Güncellemesi	31 Mar 2025

Yakın geçmiş performans güncellemeleri

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Nov 21

Recent updates

Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year

May 16

The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)

May 13

At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Apr 25

Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Mar 02

Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce

Jan 12

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Jan 03

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying

Dec 31

Progyny: Rating Downgrade On Uncertain Growth Outlook

Nov 26

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Nov 21

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Nov 18

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Oct 21

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Oct 15

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29

Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts

Sep 11 Anticipated decrease in ART cycle utilizations may negatively affect revenue due to lower fertility treatment rates.

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06

Gelir ve Gider Dağılımı

Progyny nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:PGNY Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Mar 25	1,213	52	194
31 Dec 24	1,167	54	186
30 Sep 24	1,139	57	181
30 Jun 24	1,133	63	179
31 Mar 24	1,108	61	177
31 Dec 23	1,089	62	177
30 Sep 23	1,033	52	175
30 Jun 23	957	49	165
31 Mar 23	873	43	155
31 Dec 22	787	30	144
30 Sep 22	700	42	128
30 Jun 22	617	46	113
31 Mar 22	551	56	96
31 Dec 21	501	66	80
30 Sep 21	473	90	68
30 Jun 21	450	78	61
31 Mar 21	386	58	56
31 Dec 20	345	46	62
30 Sep 20	310	3	49
30 Jun 20	272	-10	45
31 Mar 20	264	-5	41
31 Dec 19	230	-9	36
30 Sep 19	194	-6	30
30 Jun 19	160	1	27
31 Mar 19	130	-4	24
31 Dec 18	105	-6	23
31 Dec 17	49	-13	18

Kaliteli Kazançlar: PGNY yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PGNY 'nin mevcut net kar marjları (4.3%) geçen yılın (5.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PGNY son 5 yılda karlı hale geldi ve kazançlarını yıllık 14.9% oranında artırdı.

Büyüme Hızlandırma: PGNY 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: PGNY geçtiğimiz yıl negatif kazanç büyümesine ( -14.3% ) sahipti ve bu da onu Healthcare sektör ortalamasıyla ( 16.8% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: PGNY 'nin Özsermaye Getirisi ( 11.2% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/19 13:49
Gün Sonu Hisse Fiyatı	2025/05/19 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Progyny, Inc. 20 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Zhilin Long	Berenberg
Nisala Weerasuriya	Berenberg
Allen Lutz	BofA Global Research

Progyny Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Progyny, Inc. to Report Q1, 2025 Results on May 08, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. to Report Q4, 2024 Results on Feb 27, 2025

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year

The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Progyny, Inc. Revises Earnings Guidance for Full Year 2025

At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny, Inc. to Report Q1, 2025 Results on May 08, 2025

Progyny Announces Executive Appointments

Progyny, Inc., Annual General Meeting, May 22, 2025

Progyny, Inc. Announces Fred E. Cohen Notifies the Board of Directors of His Decision Not to Stand for Reelection At the 2025 Annual Meeting of Stockholders

Progyny Expands Maternal Health Support with Addition of Doula Services

Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025

Price target increased by 9.9% to US$22.14

Progyny, Inc. to Report Q4, 2024 Results on Feb 27, 2025

The Play On Progyny: Don't Chase, But Watch And Wait

Price target increased by 11% to US$20.86

Insufficient new directors

Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal

Progyny, Inc Appoints Debra Morris to Its Board of Directors and Compensation Committee

Progyny: The Growth Story Remains Intact

Investor sentiment improves as stock rises 16%

Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying

CEO & Director recently bought US$3.0m worth of stock

Investor sentiment improves as stock rises 18%

Lead Independent Director notifies of intention to sell stock

Progyny: Rating Downgrade On Uncertain Growth Outlook

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Investor sentiment deteriorates as stock falls 19%

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024

Progyny, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorates as stock falls 29%

Price target decreased by 14% to US$26.13

Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts

Progyny: Downgrading As Uncertainties Increase

Consensus EPS estimates fall by 16%

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Progyny, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024

Progyny, Inc. to Report Q2, 2024 Results on Aug 06, 2024

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

President notifies of intention to sell stock

Progyny: Recent Stock Decline Provides Buying Opportunity

Progyny, Inc. (NasdaqGS:PGNY) acquired Apryl GmbH.

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Progyny: No Change To Long-Term Outlook

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Price target decreased by 7.1% to US$43.40

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Progyny, Inc. to Report Q1, 2024 Results on May 09, 2024

Progyny, Inc., Annual General Meeting, May 23, 2024

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Executive Chairman exercised options and sold US$2.4m worth of stock

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Progyny: Long-Term Thesis Still Intact

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations